Dermata Therapeutics

(NASDAQ) DRMA

Current Price$1.31

Market Cap$5.19M

Since IPO (2021)-100%

5 YearN/A

1 Year-78%

1 Month-1%

Dermata Therapeutics Financials at a Glance

Market Cap

$5.19M

Revenue (TTM)

$0.00

Net Income (TTM)

-$7.10M

EPS (TTM)

-$5.31

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$1.31

Volume

906

Open

$1.32

Price

$1.31

Volume

906

Open

$1.32

Previous Close

$1.31

Daily Range

$1.26 - $1.35

52-Week Range

$1.10 - $8.00

Estimated Earnings Date

Aug 18, 2026

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$1.31

Volume

906

Open

$1.32

Previous Close

$1.31

Daily Range

$1.26 - $1.35

52-Week Range

$1.10 - $8.00

Estimated Earnings Date

Aug 18, 2026

DRMA News

Dermata Posts Narrower Loss in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dermata Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Gerry Proehl, MBA

Website

www.dermatarx.com

Headquarters

San Diego, CA 92130, US

DRMA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-127.91%

Return on Capital

-124.91%

Return on Assets

-95.14%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.19M

Shares Outstanding

4.02M

Volume

906

Avg. Volume

75.10K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$7.36M

EBITDA

-$7.22M

Operating Cash Flow

-$8.30M

Capital Expenditure

-$8.00

Free Cash Flow

-$8.30M

Cash & ST Invst.

$6.95M

Total Debt

$0.00

Dermata Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.19M

N/A

Market Cap/Employee

$648.58K

N/A

Employees

N/A

Net Income

-$1.85M

+19.8%

EBITDA

-$1.93M

+16.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$6.95M

-28.5%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$93.09K

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-95.14%

N/A

Return on Invested Capital

-1.15%

N/A

Free Cash Flow

-$2.48M

-28.2%

Operating Cash Flow

-$2.48M

-28.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GTBPGT Biopharma, Inc.

GTBPGT Biopharma, Inc.$0.44+2.33%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.04+6.12%

ARTLArtelo Biosciences, Inc.

ARTLArtelo Biosciences, Inc.$1.10-1.79%

ELABPMGC Holdings Inc.

ELABPMGC Holdings Inc.$1.21+6.14%

ATXIAvenue Therapeutics, Inc.

ATXIAvenue Therapeutics, Inc.$0.25-28.00%

VRAXVirax Biolabs Group Limited

VRAXVirax Biolabs Group Limited$3.26+4.82%

WINTWindtree Therapeutics, Inc.

WINTWindtree Therapeutics, Inc.$0.02+7.27%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$17.92+0.00%

NOKNokia

NOKNokia$13.03+0.00%

TAT&T

TAT&T$21.82-0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.64+0.17%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.19+0.07%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.16-0.08%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.49-0.03%

Questions About DRMA

What is the current price of Dermata Therapeutics?

Dermata Therapeutics is trading at $1.31 per share.

What is the 52-week range for Dermata Therapeutics?

Over the past 52 weeks, Dermata Therapeutics has traded between $1.10 and $8.00.

How much debt does Dermata Therapeutics have?

As of the most recent reporting period, Dermata Therapeutics reported total debt of $0.00.

How much cash does Dermata Therapeutics have on hand?

Dermata Therapeutics reported $6.95M in cash and cash equivalents in its most recent financial results.

What is Dermata Therapeutics’s dividend yield?

Dermata Therapeutics does not currently have a dividend yield.

Dermata Therapeutics

Dermata Therapeutics Financials at a Glance

DRMA News

Dermata Posts Narrower Loss in Q2

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Dermata Therapeutics

DRMA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Dermata Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DRMA

What is the current price of Dermata Therapeutics?

What is the 52-week range for Dermata Therapeutics?

How much debt does Dermata Therapeutics have?

How much cash does Dermata Therapeutics have on hand?

What is Dermata Therapeutics’s dividend yield?

Premium Investing Services